Advertisement

Topics

Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty® System and Enrollment of First Patient in DISRUPT PAD III Global Clinical Trial

08:00 EDT 21 Jun 2017 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Novel Technology Uses Sonic Pressure Waves to Treat Peripheral Artery Blockages Shockwave Medical, a pioneer in the treatment of calcified cardiovascular disease, today announced two milestones for its Lithoplasty® S...

Other Sources for this Article

For Shockwave Medical
Jessica Volchok, 310-849-7985
Jessica@healthandcommerce.com

NEXT ARTICLE

More From BioPortfolio on "Shockwave Medical Announces U.S. Commercial Availability of Lithoplasty® System and Enrollment of First Patient in DISRUPT PAD III Global Clinical Trial"

Advertisement
Quick Search
Advertisement
Advertisement